What does the video say about clinical trial enrollment for this type of study?

Clinical trial enrollment for this type of study is genuinely limited. The creator's advice that it is largely 'right place, right time' is honest and consistent with how academic transplant trials operate.

Originally posted by @chris.p.bacon857 on TikTok · 114s|Watch on TikTok

Full video transcriptClick to expand

Auto-generated transcript of @chris.p.bacon857's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

0:00Hey guys, getting my first thymoglypulin treatment or thymo as they call it.
0:05Essentially, a monoclonal antibody used in these islet cell transplants about a month before
0:11the actual transplant to help kind of temper down the immune system.
0:15Essentially, the thymo as a monoclonal antibody it attaches to some of these T cells to essentially
0:22destroy them so you're having less during the actual transplant, which will occur in about
0:27a month from now.
0:28So going through the first treatment, very excited.
0:31I know I had a lot of questions in the comment last time about a little bit about me.
0:35I've been a type 1 diabetic since I was 10 months old, so about 35 years now a little bit
0:41more and yeah, I was very excited.
0:44As far as getting into the trial, I know I've had a lot of questions about it.
0:49To be honest, for me, I just got really lucky.
0:51I think a big part of it is that I was able to be screened because I had a type A for my
0:57blood type, a positive and so that was able to give me in for the screenings and kind
1:04of went from there.
1:05I know they have not many spots open if any at all.
1:10I'm not really privy to that information.
1:14I reached out, just kind of online, went through, saw the University of Chicago was doing these
1:20trials and that's essentially how I got in.
1:25I don't know anybody out here.
1:26I don't know anybody in the study.
1:28I just kind of went through and filled out information and a lot of it's just kind of
1:35right place, right time and then the fact that I had a positive for my blood test.
1:39I'll definitely keep you guys updated on what's going on.
1:41But again, the plan is three of these thymo infusions one day after another.
1:48I'm here in the hospital, as you can see.
1:50And we'll go from there.
1:53Okay.

@chris.p.bacon857's diabetes trial video, fact-checked

Name: @chris.p.bacon857's diabetes trial video, fact-checked
Uploaded: 2025-10-28T00:20:41.000Z
Duration: 114 s

Chris P Bacon

TikTok creator

38.7K viewsWatch on TikTok →

Quick answer

The creator is a participant in what appears to be the Eledon tegoprubart phase 2 clinical trial at the University of Chicago, receiving thymoglobulin (anti-thymocyte globulin) induction immunosuppression prior to allogeneic islet cell transplantation. Thymoglobulin is a polyclonal, not monoclonal, rabbit-derived antibody preparation used to deplete recipient T cells and reduce early graft rejection. Tegoprubart, the investigational drug central to this trial, is a CD154 pathway blocker designed to extend islet graft survival by preventing T-cell co-stimulation-dependent rejection.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Start provider review Browse video library

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 3 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @chris.p.bacon857's diabetes trial video, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Systematic reviewObesity pharmacotherapy evidence2025

Emerging pharmacotherapies for obesity: A systematic review

Broad context for new and established obesity-drug categories.

PubMed

ReviewObesity pharmacotherapy evidence2026

Glucagon-like receptor agonists and next-generation incretin-based medications

Current review for incretin-based obesity medications and cardiometabolic effects.

PubMed

Provider decision path

Use local research to choose a safer review path

Direct answer

@chris.p.bacon857's diabetes trial video, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Start the provider review

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Helpful context before the funnel

Review method

See how FormBlends checks viral health claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@chris.p.bacon857's diabetes trial video, fact-checked" from Chris P Bacon. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is a participant in what appears to be the Eledon tegoprubart phase 2 clinical trial at the University of Chicago, receiving thymoglobulin (anti-thymocyte globulin) induction immunosuppression prior to allogeneic islet cell transplantation.

The reason this review is not generic is the source wording and the canonical claim label "peptides 1st thymoglobulin infusion for tegoprubart trial eledon t." In this clip, the useful excerpt is: "Hey guys, getting my first thymoglypulin treatment or thymo as they call it." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Emerging pharmacotherapies for obesity: A systematic review (2025), Glucagon-like receptor agonists and next-generation incretin-based medications (2026), and Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Tegoprubart targets the CD40L (CD154) co-stimulation pathway.

People who land here are usually comparing the Peptide social video fact-checks claim with [object Object].

The strongest next step is to compare the claim with FormBlends' Peptide social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

FormBlends verdict

Peptide social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

The creator is a participant in what appears to be the Eledon tegoprubart phase 2 clinical trial at the University of Chicago, receiving thymoglobulin (anti-thymocyte globulin) induction immunosuppression prior to allogeneic islet cell transplantation. Thymoglobulin is a polyclonal, not monoclonal, rabbit-derived antibody preparation used to deplete recipient T cells and reduce early graft rejection. Tegoprubart, the investigational drug central to this trial, is a CD154 pathway blocker designed to extend islet graft survival by preventing T-cell co-stimulation-dependent rejection.
Thymoglobulin is a polyclonal antibody preparation, not a monoclonal antibody. The distinction is not semantic: polyclonal ATG depletes T cells through multiple simultaneous binding targets, giving it broader immunosuppressive effects and a different risk profile than monoclonals.
Tegoprubart targets the CD40L (CD154) co-stimulation pathway. Earlier drugs in this class caused dangerous clotting complications; tegoprubart was re-engineered to reduce that risk, but phase 2 peer-reviewed efficacy data are not yet published.

What it may miss

It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
Compound access, legal status, and product quality still need a separate safety check.
Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

Thymoglobulin is a polyclonal antibody preparation, not a monoclonal antibody. The distinction is not semantic: polyclonal ATG depletes T cells through multiple simultaneous binding targets, giving it broader immunosuppressive effects and a different risk profile than monoclonals.
Tegoprubart targets the CD40L (CD154) co-stimulation pathway. Earlier drugs in this class caused dangerous clotting complications; tegoprubart was re-engineered to reduce that risk, but phase 2 peer-reviewed efficacy data are not yet published.
Islet transplantation is not a cure for type 1 diabetes. The landmark Shapiro et al. (2000, NEJM) Edmonton protocol showed insulin independence is achievable but often not durable beyond five to seven years without re-transplantation.
ATG induction for islet transplant has genuine supporting evidence. Posselt et al. (2010, American Journal of Transplantation) showed ATG plus costimulation blockade improved engraftment outcomes compared to calcineurin inhibitor-based regimens.
Ongoing immunosuppression after islet transplantation carries real risks including increased susceptibility to serious infection and certain malignancies. This trade-off is why transplantation is reserved for patients with severe hypoglycemia unawareness or labile diabetes.
The #diabetescure hashtag used in the caption is misleading. The creator themselves never claims a cure in the video, but the tag directs vulnerable patients toward content with accuracy it does not deliver.
Clinical trial enrollment for this type of study is genuinely limited. The creator's advice that it is largely 'right place, right time' is honest and consistent with how academic transplant trials operate.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @chris.p.bacon857 actually say?

The creator describes receiving their first thymoglobulin infusion as part of what appears to be the Eledon (tegoprubart) clinical trial at the University of Chicago. They frame thymoglobulin as "a monoclonal antibody" that "attaches to some of these T cells to essentially destroy them" ahead of an islet cell transplant scheduled about a month out. They mention three consecutive daily infusions, blood type A-positive as a screening factor, and 35-plus years living with type 1 diabetes since infancy. They also correctly hedge that trial spots are limited and they got in largely through luck and timing. That framing is refreshingly honest compared to most clinical trial content on TikTok, which tends toward hype.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Chris P Bacon · TikTok creator

38.7K views on this video

1st thymoglobulin infusion for tegoprubart trial! #eledon #t1d #type1diabetes #diabetescure #clinicaltrial

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about thymoglobulin?

Thymoglobulin is a polyclonal antibody preparation, not a monoclonal antibody. The distinction is not semantic: polyclonal ATG depletes T cells through multiple simultaneous binding targets, giving it broader immunosuppressive effects and a different risk profile than monoclonals.

What does the video say about tegoprubart targets the cd40l (cd154) co-stimulation pathway. earlier drugs in?

Tegoprubart targets the CD40L (CD154) co-stimulation pathway. Earlier drugs in this class caused dangerous clotting complications; tegoprubart was re-engineered to reduce that risk, but phase 2 peer-reviewed efficacy data are not yet published.

Islet transplantation is not a cure for type 1 diabetes. The landmark Shapiro et al. (2000, NEJM) Edmonton protocol showed insulin independence is achievable but often not durable beyond five to seven years without re-transplantation?

What does the video say about atg induction for?

ATG induction for islet transplant has genuine supporting evidence. Posselt et al. (2010, American Journal of Transplantation) showed ATG plus costimulation blockade improved engraftment outcomes compared to calcineurin inhibitor-based regimens.

What does the video say about ongoing immunosuppression after?

Ongoing immunosuppression after islet transplantation carries real risks including increased susceptibility to serious infection and certain malignancies. This trade-off is why transplantation is reserved for patients with severe hypoglycemia unawareness or labile diabetes.

What does the video say about the #diabetescure hashtag used in the caption?

The #diabetescure hashtag used in the caption is misleading. The creator themselves never claims a cure in the video, but the tag directs vulnerable patients toward content with accuracy it does not deliver.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.